Search - tctmd.com

Displaying 381 - 400 of 619

Sort: Relevancy | Date

Presentation ACC 2018

The ODYSSEY OUTCOMES Trial: Topline Results Alirocumab in Patients After Acute Coronary Syndrome

Presenter: Philippe Gabriel Steg

March 10, 2018

News Conference News ACC 2018

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

Michael O'Riordan

March 10, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Daily News

Obesity Robs People of CVD-Free Years and Ups the Risk of Dying Young

Michael O'Riordan

March 02, 2018

News Daily News

Roughly Half of Obese Patients Who Have Bariatric Surgery Are Off Type 2 Diabetes Meds at 6 Years

Michael O'Riordan

February 19, 2018

News Daily News

No Cardiovascular Benefit With Omega-3 Fatty Acid Supplements: Meta-analysis

Michael O'Riordan

February 02, 2018

News Daily News

TCTMD’s Top 10 Most Popular Stories for January 2018

Shelley Wood

January 31, 2018

News Daily News

‘Call to Action’ in India, Where Hypertension and Diabetes Loom Large

Michael O'Riordan

January 30, 2018

News Daily News

Role of Lp(a) Still to Be Determined, but NHLBI Sees a Path Forward

Michael O'Riordan

January 09, 2018

News Daily News

Cardiovascular Disease and Risk Factors Increasing Among Patients Undergoing Noncardiac Surgery

Yael L. Maxwell

January 09, 2018

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

Subclinical Atherosclerosis Evident in Half of Adults Without CVD Risk Factors

Michael O'Riordan

December 12, 2017

News Daily News

Myocardial Injury After Noncardiac Surgery Linked With Higher 1-Year Mortality

Caitlin E. Cox

December 05, 2017

News Daily News

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

Michael O'Riordan

December 04, 2017

News Daily News

Genetic Study Hints at Role of Lipids in AAA Risk

Michael O'Riordan

November 30, 2017

Top Stories in Cardiology, November 2017

Podcast Heart Sounds

Targeting Inflammation in Atherosclerosis: Has CANTOS Nailed It?

Presenter: Sanjay Kaul

November 16, 2017

News Conference News AHA 2017

Sustained Blood Pressure Reductions With Gastric Bypass Surgery: GATEWAY

Michael O'Riordan

November 16, 2017

News Conference News AHA 2017

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

Yael L. Maxwell

November 13, 2017

News Conference News AHA 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Michael O'Riordan

November 13, 2017

Advertisement

The ODYSSEY OUTCOMES Trial: Topline Results Alirocumab in Patients After Acute Coronary Syndrome

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Obesity Robs People of CVD-Free Years and Ups the Risk of Dying Young

Roughly Half of Obese Patients Who Have Bariatric Surgery Are Off Type 2 Diabetes Meds at 6 Years

No Cardiovascular Benefit With Omega-3 Fatty Acid Supplements: Meta-analysis

TCTMD’s Top 10 Most Popular Stories for January 2018

‘Call to Action’ in India, Where Hypertension and Diabetes Loom Large

Role of Lp(a) Still to Be Determined, but NHLBI Sees a Path Forward

Cardiovascular Disease and Risk Factors Increasing Among Patients Undergoing Noncardiac Surgery

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Subclinical Atherosclerosis Evident in Half of Adults Without CVD Risk Factors

Myocardial Injury After Noncardiac Surgery Linked With Higher 1-Year Mortality

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

Genetic Study Hints at Role of Lipids in AAA Risk

Top Stories in Cardiology, November 2017

Targeting Inflammation in Atherosclerosis: Has CANTOS Nailed It?

Sustained Blood Pressure Reductions With Gastric Bypass Surgery: GATEWAY

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content